Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures

European Journal of Cardio-thoracic Surgery

Volumn 33, Issue 4, 2008, Pages 723-727

  Elia, Stefano ^a   Massoud, Renato ^a   Guggino, Gianluca ^b   Cristino, Benedetto ^a   Cortese, Claudio ^a   De Massimi, Alessia Raffaella ^a   Zenobi, Rossella ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

Diagnostic procedure; Enzyme immunoassay; M2 pyruvate kinase; Pleural effusion; Thoracic malignancies; Thoracoscopy; Tumor markers

Indexed keywords

GLYCOLYTIC ENZYME; PYRUVATE KINASE ISOENZYME M 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INVASIVE PROCEDURE; ISOENZYME ANALYSIS; LABORATORY DIAGNOSIS; MALE; PLASMA; PLEURA EFFUSION; PLEURA FLUID; PREDICTION AND FORECASTING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR CLASSIFICATION;

ADULT; AGED; BODY FLUIDS; CLINICAL ENZYME TESTS; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PYRUVATE KINASE; SENSITIVITY AND SPECIFICITY; THORACIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 40649126095     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2008.01.014     Document Type: Article

References (25)

1. Lee J.H., and Chang J.H. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest 128 (2005) 2298-2303
2. Neragi-Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 54 (2006) 1-9
3. Light R.W. Pleural effusion. N Engl J Med 346 (2002) 1971-1977
4. Porcel J.M., Vives M., Esquerda A., Salud A., Perez B., and Rodriguez-Panadero F. Use of a panel of tumor markers (Carcinoembryonic Antigen, Cancer Antigen 125, Carbohydrate Antigen 15-3, and Cytokeratin 19 Fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 126 (2004) 1757-1763
5. Prakash U.B., and Reiman H.M. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc 60 (1985) 158-164
6. Edmondstone W.M. Investigation of pleural effusion: comparison between fibreoptic thoracoscopy, needle biopsy and cytology. Resp Med 84 (1990) 23-26
7. Maskell N.A., Gleeson F.V., and Davies R.J. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomized controlled trial. Lancet 361 (2003) 1326-1330
8. Loddenkemper R. Medical thoracoscopy. In: Light R.W., and Gary Lee Y.C. (Eds). Textbook of pleural diseases (2003), Arnold, London 498-512
9. Shitrit D., Zingerman B., Shitrit A.B., Shlomi D., and Kramer M.R. Diagnostic value of Cyfra 21-1, CEA, Ca 19-9, Ca 15-3, and Ca 125 assays in pleural effusions: analysis of 116 cases and review of literature. Oncologist 10 (2005) 501-507
10. Fetsch P.A., and Abati A. Immunocytochemistry in effusion cytology. Cancer 93 (2001) 293-308
11. Villena V., Lopez Encuentra A., Echave-Sustaeta J., Martin-Escribano P., Ortuno-de-Solo B., and Estenoz-Alfaro J. Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, Ca 15-3 and Ca 72.4. Lung Cancer 40 (2003) 89-294
12. Alatas F., Alatas O., Metintas M., Colak O., Harmanci E., and Demir S. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung cancer 31 (2001) 9-16
13. Kuralay F., Tokgoz Z., and Comlekci A. Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin. Clin Chim Acta 300 (2000) 43-55
14. Mazurek S., Boschek C.B., Hugo F., and Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Sem Cancer Biol 15 (2005) 300-308
15. Ventrucci M., Cipolla A., Racchini C., Casadei R., Simoni P., and Gullo L. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 49 (2004) 1149-1155
16. Zhang B., Chen J., Chen D., Wang G., and Shen P. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J Gastroenterol 10 (2004) 1643-1646
17. Light R.W. Tumor markers in undiagnosed pleural effusions. Chest 126 (2004) 1721-1722
18. Passebosc-Faure K., Li G., Lambert C., Cottier M., Gentil-Perret A., Fournel P., Perol M., and Genin C. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res 11 (2005) 6862-6867
19. Mohanty S.K., and Dey P. Serous effusions. Diagnosis of malignancy beyond cytomorphology. An analytic review. Postgrad Med J 79 (2003) 569-574
20. Martensson G., Petterson K., and Thiringer G. Differentiation between malignant and non-malignant pleural effusion. Eur J Resp Dis 67 (1985) 326-334
21. Diacon A.H., Van de Wal B.W., Wyser C., Smedema J.C., Bezuidenhout J., Bolliger C.T., and Walzl G. Diagnostic tools in tuberculous pleurisy: a direct comparative study. Eur Respir J 22 (2003) 589-591
22. Fenton K.N., and Richardson J.D. Diagnosis and management of malignant pleural effusions. Am J Surg 170 (1995) 69-74
23. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 162 (2000) 1987-2001
24. Ferrer J., Roldan J., Teixidor J., Pallisa E., Gich I., and Morell F. Predictors of pleural malignancy in patients with pleural effusion undergoing thoracoscopy. Chest 127 (2005) 1017-1022
25. Schneider J., Neu K., Velcovsky, Morr H., and Eigenbrodt. Tumor M2-pyruvate kinase in the follow up of inoperable lung cancer patients: a pilot study. Cancer Lett 193 (2003) 91-98